Anti-Ret Rabbit Monoclonal Antibody for WB, IF/ICC, ELISA - P07949

Core Product Specifications and Parameters

Biological Background: Ret Function and Localization

• Ret is a receptor tyrosine kinase encoded by the RET proto-oncogene (also known as CDHF12, CDHR16, PTC) and belongs to the cadherin superfamily.
• Receptor activation requires binding of GDNF family ligands (GDNF, NRTN, ARTN, PSPN, GDF15) to specific GDNFR-α coreceptors, leading to autophosphorylation and downstream MAPK and AKT signaling. Related references: PMID:21994944, PMID:23333276, PMID:24560924
• Functions as a dependence receptor in pituitary somatotrophs, promoting survival in the presence of GDNF but triggering apoptosis upon ligand withdrawal. Related references: PMID:20616503, PMID:21994944
• Involved in organogenesis: required for development of the enteric nervous system, kidneys, and gut-associated lymphoid tissues (by similarity), and triggers differentiation of rapidly adapting mechanoreceptors. Related references: PMID:20064382
• Mediates GDF15-induced aversive responses in the brainstem, including nausea and appetite loss, via the GFRAL coreceptor. Related references: PMID:28846097, PMID:28846099, PMID:28953886
• Regulates cell adhesion and migration through caspase-mediated cleavage and integrin-dependent mechanisms. Related references: PMID:20702524, PMID:21357690
• Phosphorylates PTK2/FAK1 upon activation. Related references: PMID:21454698
• Alternative splicing generates isoforms with differential signaling potency; isoform 1 induces stronger MAPK activation than isoform 2. Mutations in RET are associated with multiple endocrine neoplasia type 2 (MEN2A/MEN2B) and Hirschsprung disease.

Experimental Guidance and Technical Tips

• The immunogen targets a C-terminal peptide (aa 1000–1100) within the kinase domain; thus the antibody may recognize full-length Ret (~124 kDa) and possibly C-terminal fragments or cleaved isoforms.
• For Western blotting, consider using reducing conditions and validate the expected molecular weight; be aware that glycosylation and proteolytic processing may produce additional bands.
• In immunofluorescence/ICC, anticipate membrane and endosomal staining; optimize fixation and permeabilization protocols for your cell type.
• Include appropriate controls such as known Ret-expressing cell lines (e.g., neuroendocrine or thyroid cancer cells) and imatinib-treated samples to confirm specificity.
• For ELISA applications, titrate the antibody and use a matched pair strategy with a detection antibody for optimal sensitivity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines IVD raw material procurement for diagnostic developers and research institutions, providing validated antibody pairs, bulk ancillary reagents, and access to rare target products. This monoclonal antibody against the Ret proto-oncogene supports investigations in oncology, neurodevelopment, and signal transduction pathways. With a comprehensive one-stop supply chain, CamelBio bridges the gap between concept and clinic, ensuring you obtain the critical reagents needed for assay development and validation.